COOPER GRAHAM K 4

What Happened Graham K. Cooper, a director of Beam Therapeutics Inc. (BEAM), received a derivative equity award on 2026-06-03 covering 19,676 shares. The Form 4 reports the acquisition as a grant/award (transaction code A) with an acquisition amount of $0 on the filing. This was not a cash purchase or sale of shares but a director compensation award.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely filing).
• Transaction type: Grant/Award (derivative instrument), 19,676 shares, reported acquisition amount $0.
• Shares owned after transaction: Not specified in the provided filing data.
• Footnote: The option vests in full on the earlier of the first anniversary of the grant date and immediately prior to the next year’s annual meeting of stockholders, subject to continued service on the board.
• No indication of a 10% owner, 10b5-1 plan, or tax-withholding sale shown in this report.

Context This appears to be an equity award (an option-type derivative) granted as part of director compensation rather than an open-market trade. The award vests under a one-year condition tied to continued board service, and no cash was reported as paid at grant. Such grants are common for non-employee directors and do not by themselves signal buying or selling intent; any future exercise or sale would generate further filings.